Five things to know:
1. The U.S. degenerative disc disease treatment market is expected to grow 5.9 percent from 2021 to 2028.
2. Key trends in the market include a pipeline of treatments expected to drive growth. The report cited Minneapolis-based University of Minnesota’s clinical trial of a combination of drugs and Iowa City-based University of Iowa’s clinical trial of Tranexamic Acid in lumbar interbody spinal fusion.
3. Late stage treatment is expected to hold a dominant position in the market.
4. Key players in the market are focusing on developing and launching novel therapeutic treatments.
5. Major companies mentioned in the report include AnGes, Bone Therapeutics, DiscGenics, Ankasa Regenerative Therapies, Smith+Nephew and Spine BioPharma.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
